Global Central Nervous System Therapeutic Market Size & Outlook
Global central nervous system therapeutic market, 2021-2033 (US$M)
Related Markets
Global central nervous system therapeutic market highlights
- The global central nervous system therapeutic market generated a revenue of USD 138,594.5 million in 2025 and is expected to reach USD 273,320.3 million by 2033.
- The market is expected to grow at a CAGR (2026 - 2033) of 9.1% by 2033.
- In terms of segment, neurodegenerative diseases accounted for a revenue of USD 51,404.1 million in 2025.
- Neurodegenerative Diseases is the most lucrative disease segment registering the fastest growth during the forecast period.
- In terms of region, North America was the largest revenue generating market in 2025.
- Country-wise, India is expected to register the highest CAGR from 2026 to 2033.
Global data book summary
| Market revenue in 2025 | USD 138,594.5 million |
| Market revenue in 2033 | USD 273,320.3 million |
| Growth rate | 9.1% (CAGR from 2026 to 2033) |
| Largest segment | Neurodegenerative diseases |
| Fastest growing segment | Neurodegenerative Diseases |
| Historical data covered | 2021 - 2024 |
| Base year for estimation | 2025 |
| Forecast period covered | 2026 - 2033 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Neurovascular Diseases, CNS Trauma, Mental Health, Neurodegenerative Diseases, Infectious Diseases, CNS Cancer |
Other key industry trends
- In terms of revenue, the North America accounted for 41.8% of the global central nervous system therapeutic market in 2025.
- By country, the U.S. is projected to lead the global market in terms of revenue in 2033.
- By country, India is the fastest growing regional market and is projected to reach USD 3,147.9 million by 2033.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Central Nervous System Therapeutic Market Scope
Central Nervous System Therapeutic Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| Biogen Inc | View profile | 7570 | 225 Binney Street, Cambridge, MA, United States, 02142 | https://www.biogen.com |
| AstraZeneca PLC | View profile | 89900 | 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, United Kingdom, CB2 0AA | https://www.astrazeneca.com |
| Otsuka Pharmaceutical | View profile | 251-500 | Tokyo, Tokyo, Japan, Asia | https://www.otsuka.co.jp/en/ |
| Eli Lilly and Co | View profile | 43000 | Lilly Corporate Center, Indianapolis, IN, United States, 46285 | https://www.lilly.com |
| Merck & Co Inc | View profile | 72000 | 126 East Lincoln Avenue, Rahway, NJ, United States, 07065 | https://www.merck.com |
| Pfizer Inc | View profile | 88000 | 66 Hudson Boulevard East, New York, NY, United States, 10001-2192 | https://www.pfizer.com |
| Teva Pharmaceutical Industries Ltd | View profile | 37851 | 124 Dvora HaNevi’a Street, Tel Aviv, Israel, 6944020 | https://www.tevapharm.com |
| Novartis AG ADR | View profile | 76057 | Lichtstrasse 35, Basel, Switzerland, 4056 | https://www.novartis.com |
| Johnson & Johnson | View profile | 134400 | One Johnson and Johnson Plaza, New Brunswick, NJ, United States, 08933 | https://www.jnj.com |
Global central nervous system therapeutic market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to central nervous system therapeutic market will help companies and investors design strategic landscapes.
Neurodegenerative diseases was the largest segment with a revenue share of 37.09% in 2025. Horizon Databook has segmented the Global central nervous system therapeutic market based on neurovascular diseases, cns trauma, mental health, neurodegenerative diseases, infectious diseases, cns cancer covering the revenue growth of each sub-segment from 2021 to 2033.
- Global Central Nervous System Therapeutic Disease Outlook (Revenue, USD Million, 2021-2033)
- CNS Trauma
- Neurodegenerative Diseases
- Parkinsosns Disease
- Amytrophic Lateral Sclerosis
- Alzheimers Disease
- Huntingtons Disease
- Multiple Sclerosis
- Others
- CNS Cancer
- Others
- Neurovascular Diseases
- Infectious Diseases
- Mental Health
- Others
- Anxiety Disorders
- Mood Disorders
- Epilepsy
- Psychotic Disorders
- Global Central Nervous System Therapeutic Drug Class Outlook (Revenue, USD Million, 2021-2033)
- Antidepressants
- Antiepileptics (AEDs)
- Neuroprotective Agents
- Antipsychotics
- Dopaminergic Agents
- Immunomodulators
- Others
- Global Central Nervous System Therapeutic Distribution Channel Outlook (Revenue, USD Million, 2021-2033)
- Others
- Retail Pharmacy
- Hospital Pharmacy
Reasons to subscribe to Global central nervous system therapeutic market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Global central nervous system therapeutic market databook
-
Our clientele includes a mix of central nervous system therapeutic market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of global-level data and insights on the Global central nervous system therapeutic market , including forecasts for subscribers. This global databook contains high-level insights into Global central nervous system therapeutic market from 2021 to 2033, including revenue numbers, major trends, and company profiles.
Partial client list
Global central nervous system therapeutic market size, by regions, 2021-2033 (US$M)
Top 10 countries: Central nervous system therapeutic market size, 2025 (US$M)
Global central nervous system therapeutic market share, by drug class, 2025 & 2033 (%, US$M)
Central nervous system therapeutic market: Opportunity assessment by country
Global central nervous system therapeutic market, by region, 2025 (US$M)
Related industry reports
Related statistics
No records
No related statistics found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
